INSANE: Absci - The Real Truth

Eli Lilly just placed a $40 million bet on the next injectable boom

The GLP-1 maker’s latest AI investment targets drug discovery and the future of consumer medicine.

Fortune · Jul 1

2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk

Absci's AI drug development platform is compelling, and its pipeline is promising...but can the company overcome execution hurdles to live up to analyst hype?

MarketBeat · Oct 13, 2025

Absci Boosts AI-Powered Drug Discovery With Oracle And AMD Collaboration

Absci Inc. (NASDAQ:ABSI) on Thursday collaborated with Oracle Corporation’s (NASDAQ:ORCL) Oracle Cloud Infrastructure (OCI) and AMD Inc. (NASDAQ:AMD) to accelerate generative AI-driven drug discovery.

Benzinga · Sep 11, 2025

3 AI-Driven Drug Stocks to Buy Before They Breakout

The pharma sector is expected to undergo a huge disruption, thanks to the impact of artificial intelligence. Here are three companies that Wall Street analysts think could benefit, based on their AI-driven R&D.

Barchart · Feb 29, 2024

AstraZeneca Partners With AI Company to Find Cure For Cancer

Absci, a drug and target discovery company, has been harnessing the power of deep learning AI to develop new and existing disease treatments.

International Business Times UK · Dec 5, 2023

Absci's Return On Capital Employed Insights

Absci (NASDAQ:ABSI) brought in sales totaling $819.00 thousand during Q1 according to data provided by Benzinga Pro. However, earnings decreased 17.2%, resulting in a loss of $29.49 million.

Benzinga · Jun 15, 2022

Here's Why Absci Corp Shares Are Falling

Absci Corp (NASDAQ: ABSI) shares are trading lower by 9.2% at $6.79 after the company reported fourth-quarter earnings results.

Benzinga · Mar 23, 2022

Absci's Return On Capital Employed Overview

Absci (NASDAQ:ABSI) brought in sales totaling $1.45 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 6.48%, resulting in a loss of $25.17 million.

Benzinga · Mar 23, 2022